Sarepta Therapeutics
Sarepta Therapeutics, Inc., a leading biotechnology company headquartered in the United States, is at the forefront of developing innovative genetic medicine for rare diseases, particularly Duchenne muscular dystrophy (DMD). Founded in 1980, Sarepta has achieved significant milestones, including the development of its pioneering exon-skipping therapies, which offer unique treatment options for patients with DMD. With a strong focus on advancing precision medicine, Sarepta's core products, such as eteplirsen and golodirsen, utilise cutting-edge technology to address the underlying genetic causes of muscular dystrophies. The company has established a prominent market position, recognised for its commitment to transforming the lives of patients through groundbreaking therapies. As it continues to expand its operational reach, Sarepta remains dedicated to innovation and excellence in the biotechnology industry.
DitchCarbon Score
How does Sarepta Therapeutics's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sarepta Therapeutics's score of 21 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sarepta Therapeutics's reported carbon emissions
In 2023, Sarepta Therapeutics, headquartered in the US, reported total carbon emissions of approximately 3,428,000 kg CO2e for Scope 1 and about 5,000,000 kg CO2e for Scope 2. This reflects a slight increase in emissions compared to 2022, where Scope 1 emissions were around 2,701,000 kg CO2e and Scope 2 emissions were approximately 4,789,000 kg CO2e. Sarepta has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives as part of their climate commitments. The absence of reduction targets indicates a potential area for future development in their sustainability strategy. Overall, while Sarepta Therapeutics has made strides in tracking and reporting their emissions, the lack of comprehensive reduction goals suggests that further action may be necessary to align with industry standards for climate accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,701,000 | 0,000,000 |
| Scope 2 | 4,789,000 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sarepta Therapeutics is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
